Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

86.28 -1.00 (-1.15%)

Streaming Delayed Price Updated: 11:19 AM EDT, Apr 15, 2026 Add to My Watchlist

Price and Volume

Volume	105,536
Open	88.07
Bid (Size)	86.21 (200)
Ask (Size)	86.87 (100)
Prev. Close	87.28
Today's Range	85.90 - 90.00
52wk Range	55.31 - 122.20
Shares Outstanding	66,684,077
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026

April 09, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal

April 07, 2026

In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive...

Via MarketMinute

Performance

YTD	-17.8%	-17.8%
1 Month	-4.7%	-4.7%
3 Month	-20.0%	-20.0%
6 Month	-18.0%	-18.0%
1 Year	+43.5%	+43.5%

More News

Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit

April 07, 2026

Via Finterra

Rhythm Pharmaceuticals (NASDAQ:RYTM) Posts Q4 Revenue Beat and Narrows Loss ↗

February 26, 2026

Via Chartmill

RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March ↗

January 09, 2026

Via Stocktwits

Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar

April 06, 2026

Via MarketMinute

Rhythm Pharmaceuticals Announces Changes to Board of Directors

April 03, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Is This Weight Loss Drug Stock a Buy After a New Approval? ↗

March 31, 2026

Via The Motley Fool

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

March 26, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

March 19, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial

March 16, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗

March 04, 2026

Via The Motley Fool

Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗

March 04, 2026

Via The Motley Fool

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

March 01, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharma (RYTM) Earnings Call Transcript ↗

February 26, 2026

Via The Motley Fool

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

February 26, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗

February 22, 2026

Via The Motley Fool

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗

February 22, 2026

Via The Motley Fool

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗

February 22, 2026

Via The Motley Fool

$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗

February 22, 2026

Via The Motley Fool

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026

February 17, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Prediction: These 3 Stocks Will Crush the Market in 2026 ↗

February 16, 2026

Via The Motley Fool

Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit

February 05, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

This High-Flying Growth Stock Is Hiding in Plain Sight ↗

February 02, 2026

Via The Motley Fool

Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones

January 09, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Rhythm Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Rhythm Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Rhythm Pharmaceuticals, Inc. - Common Stock trade on?

Rhythm Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock is RYTM on the Nasdaq Stock Market

What is the current price of Rhythm Pharmaceuticals, Inc. - Common Stock?

The current price of Rhythm Pharmaceuticals, Inc. - Common Stock is 86.28

When was Rhythm Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Rhythm Pharmaceuticals, Inc. - Common Stock was at 04/15/26 11:19 AM ET

What is the market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock is 5.75B

How many shares of Rhythm Pharmaceuticals, Inc. - Common Stock are outstanding?

Rhythm Pharmaceuticals, Inc. - Common Stock has 6B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.